Overview
Zakłady Farmaceutyczne Polpharma is the largest Polish manufacturer of pharmaceuticals and active pharmaceutical ingredients. The company actively operates in the markets of Central and Eastern Europe, the Caucasus, and Central Asia.
Financials
Revenue history (in m)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
Industry
Bank accounts
Registered as a VAT taxpayer on 1993-07-05. Active
26 1030 1117 0000 0000 0101 7220- 67 1030 1508 0000 0008 1637 2009
- 94 1030 1508 0000 0008 1637 2008
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
12 notices recorded in the Court and Commercial Gazette (MSiG).
| Publication date | Event | |
|---|---|---|
| Sep 30, 2026 | Bankruptcy notice | |
| Feb 1, 2024 | Merger registered | |
| Jan 12, 2024 | Merger registered | |
| Apr 27, 2021 | Merger registered | |
| Jan 18, 2021 | Shareholders' meeting convened |
Public aid
48 public aid cases recorded, with a total value of $202,480,103.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Mar 31, 2026 | Regional investment aid | —— | PIERWSZY MAZOWIECKI URZĄD SKARBOWY W WARSZAWIE | |
| Mar 31, 2026 | Regional investment aid | —— | PIERWSZY MAZOWIECKI URZĄD SKARBOWY W WARSZAWIE | |
| Dec 19, 2025 | Aid for research and development projects: experimental development | —— | Dyrektor Narodowego Centrum Badań i Rozwoju |
European Funds
7 projects co-financed from European Funds recorded, with total EU co-financing of $22,474,941.
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2025-09-01 | Opracowanie innowacyjnej platformy technologiczno - analitycznej do produkcji leków zawierających oligonukleotydy w formie gotowej do użycia. | $7.7M$7,651,569 | Fundusze Europejskie dla Nowoczesnej Gospodarki | |
| 2024-11-01 | Opracowanie i rozwój innowacyjnego rozwiązania – złożonego, dwuskładnikowego produktu leczniczego, ukierunkowanego na terapię nadciśnienia tętniczego | $2.5M$2,467,546 | Fundusze Europejskie dla Nowoczesnej Gospodarki | |
| 2023-11-01 | Opracowanie narzędzia wykorzystującego algorytmy sztucznej inteligencji do prognozowania wielkości sprzedaży oraz planowania strategii marketingowych dla produktów farmaceutycznych | $2.6M$2,632,074 | Fundusze Europejskie dla Nowoczesnej Gospodarki |
Tenders
25 tenders recorded as contracting authority.
Notices (contracting authority)
| Publication date | Subject | Type | Amount | |
|---|---|---|---|---|
| Jan 11, 2017 | Sprzęt biomedyczny | Contract award notice | —— | |
| Jan 11, 2017 | Sprzęt laboratoryjny, optyczny i precyzyjny (z wyjątkiem szklanego) | Contract award notice | —— | |
| Jan 11, 2017 | Sprzęt laboratoryjny, optyczny i precyzyjny (z wyjątkiem szklanego) | Contract award notice | —— |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | Integrated permit | Active |
Authorized Representatives
Manner of representation
Joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations of will and sign on behalf of the company.
Supervisory board
Ownership
| Owner |
|---|
Polpharma Group Holding B.v. |
Beneficial owners
| Person | Rights | |
|---|---|---|
Jerzy Andrzej, Stanisław Starak (79)  | Za pośrednictwem innej spółki |
Capital group
| Name | Ownership |
|---|---|
| 100% | |
Polpharma Biuro Hanlowe Sp. z o.o | 100% |
| 100% |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Celon PharmaS.A. | $1,530,249,310.95 | celonpharma.com | ||
| Adamed PharmaS.A. | $541,927,181.76 | adamed.com.pl | ||
| Aflofarm Farmacja Polskasp. z o.o. | $302,019,142.07 | aflofarm.pl | ||
| Anpharm Przedsiębiorstwo FarmaceutyczneS.A. | $160,174,284.28 | anpharm.pl |
Change history
| Date | Event | |
|---|---|---|
| 2026-09-30 | Share capital change (100,207,830.00 PLN → 101,015,400.00 PLN) | |
| 2009-07-10 | Share capital change (105,292,020.00 PLN → 100,207,830.00 PLN) | |
| 2007-11-15 | Share capital change (226,429,050.00 PLN → 105,292,020.00 PLN) | |
| 2004-01-27 | Share capital change (202,619,050.00 PLN → 226,429,050.00 PLN) | |
| 2002-08-22 | Entered in the register |
FAQ
Last updated: 2026-09-30